Deutsche Bank Revists The Story on Teva Pharma (TEVA); Many Catalysts Ahead, Floor Established at $35

Article Stock Quotes (1) Comments (0)

Deutsche Bank maintains a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $48.00.

Analyst, David M. Steinberg, said, "With several near term catalysts (Copaxone court decision, upcoming analyst meeting, etc.), we like Teva’s risk-reward profile at current levels. Moreover, Teva’s FCF yield is ~2x the average of both Major and Generic Pharma."

Steinberg sees approx. $10 of upside vs. $3/share downside, and that the stock being close to five year lows, it makes sense to revisit this story considering several upcoming catalysts.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $38.10 yesterday, with a 52 week range of $35.00-$49.72.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
• Goldman Sachs Maintains Sell on Microsoft (MSFT)
• Goldman Sachs Upgrades Meritor (MTOR) to Buy

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Deutsche Bank

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?